GVHD and Dry Eye

Ocular graft-versus-host disease (oGVHD) is one of the most common chronic complications of allogeneic stem cell or bone marrow transplant — and one of the most severe forms of dry eye disease. According to the TFOS DEWS II Pathophysiology Report, more than half of patients who develop chronic GVHD experience ocular involvement, often with significant ocular surface disease that can threaten vision if untreated. Dr. Y. Shira Kresch evaluates and treats GVHD-related dry eye at our Southfield, MI clinic, often coordinating with oncology and the transplant team.

If you have received a stem cell or bone marrow transplant — or you care for someone who has — and you are experiencing eye dryness, burning, redness, or vision changes, those symptoms deserve prompt evaluation. Ocular GVHD ranges from mild dry eye to severe ocular surface disease, and early intervention significantly improves long-term outcomes.

What Is Ocular GVHD?

Graft-versus-host disease (GVHD) is a condition that can occur after allogeneic stem cell or bone marrow transplant, when the donor immune cells recognize the recipient’s tissues as foreign and attack them. GVHD can affect almost any organ, but the eyes are one of the most commonly involved sites in chronic GVHD.

When the donor immune cells target the lacrimal glands, conjunctiva, and corneal nerves, the result is a particularly severe form of dry eye that combines features of autoimmune aqueous-deficient disease with chronic inflammatory ocular surface damage.

How GVHD Causes Dry Eye

The mechanism is multi-faceted and progressive:

Lacrimal Gland Destruction

Donor immune cells infiltrate the lacrimal glands, gradually destroying the tear-producing tissue. This produces severe aqueous-deficient dry eye that is often present alongside (and worse than) ordinary aqueous-deficient dry eye.

Meibomian Gland Damage

The Meibomian glands of the eyelids are also affected by the immune attack, contributing to Meibomian Gland Dysfunction and an evaporative component to the dry eye picture. Many GVHD patients have mixed dry eye with both aqueous-deficient and evaporative components.

Conjunctival and Corneal Inflammation

Direct inflammation of the conjunctiva (the membrane covering the white of the eye) and the cornea contributes to ongoing surface damage. Corneal scarring, persistent epithelial defects, and even corneal melt can occur in severe cases.

Reduced Corneal SensationThe corneal nerves themselves are affected, reducing the protective sensory feedback that normally triggers tear production and protective blink reflexes.

Symptoms of Ocular GVHD

Severe dryness, often worse than expected
Burning, stinging, or constant grittiness
Photophobia (light sensitivity)
Foreign body sensation
Eye pain
Eyelid swelling or redness
Excessive watering paradoxically combined with dryness
Stringy or thick mucus discharge
Blurred or fluctuating vision
Visible eyelid scarring or deformities in advanced cases
Concurrent dry mouth, skin changes, or other GVHD symptoms in other organs

Symptoms can begin as early as a few months after transplant or develop years later. The variability and gradual onset can lead to delayed diagnosis if the eye care provider is not familiar with post-transplant ocular complications.

When to Seek Specialty Eye Care After Transplant

According to American Academy of Ophthalmology guidance, all patients who have received allogeneic stem cell or bone marrow transplant should establish baseline eye care and have regular monitoring, even before symptoms develop. Specifically:

Within 6 months post-transplant for a baseline examination
At first onset of any ocular symptoms
Periodic ongoing surveillance based on overall GVHD status

Early intervention preserves more functional tissue than late intervention. Severe GVHD eye disease that has been allowed to progress over years is significantly harder to manage than early-detected disease.

How We Diagnose Ocular GVHD

At your comprehensive dry eye evaluation, Dr. Kresch performs the standard diagnostic workup plus additional elements specific to post-transplant cases:

Detailed transplant history — type of transplant, time since transplant, current GVHD status in other organs, current immunosuppression
Schirmer test — typically severely reduced in GVHD
Tear film breakup time and osmolarity
Meibography — to assess Meibomian gland involvement
Ocular surface staining — to identify the extent and severity of corneal and conjunctival damage
Corneal sensation testing — to assess neurotrophic component
Lid margin and conjunctival assessment — for fibrosis, scarring, and other GVHD-specific changes
Coordination with oncology — to align eye treatment with systemic GVHD management

How We Treat Ocular GVHD

Aggressive Lubrication

Preservative-free artificial tears used frequently throughout the day. For severe cases, autologous serum tears (compounded from the patient’s own blood) provide growth factors and proteins that promote ocular surface healing.

Anti-Inflammatory Therapy

Topical anti-inflammatory medications including cyclosporine, lifitegrast, and short courses of corticosteroids help control the chronic immune-mediated inflammation. Systemic immunosuppression for the underlying GVHD also benefits the eyes.

Punctal Plugs

Punctal occlusion conserves what limited tear production remains. For severe cases, punctal cautery (permanent closure) may be more durable than removable plugs.

Scleral Lenses

Scleral lenses are often life-changing for ocular GVHD. The continuous saline reservoir behind the lens provides constant corneal hydration, mechanical protection from environmental exposure, and a healing environment for the damaged corneal surface. For patients with severe corneal involvement, scleral lenses can also provide visual rehabilitation when other vision correction is no longer effective.

Concurrent Treatment of MGD

When Meibomian Gland Dysfunction is significant, treatments like IPL, RF, and LLLT may be appropriate, often as part of a combined treatment protocol. These need careful coordination with the patient’s immunosuppression status.

Surgical Interventions for Severe Cases

In the most severe cases, surgical interventions including amniotic membrane grafts, salivary gland transplants, or other reconstructive procedures may be considered. These are last-resort interventions but can be valuable for vision-threatening disease.

Coordination with Transplant Team

The best outcomes come from coordinated care between the eye specialist, the transplant team, and any other specialists managing GVHD in other organs. Dr. Kresch routinely communicates with referring physicians.

Why Early Treatment Matters

Ocular GVHD is progressive without treatment. Chronic inflammation gradually damages the lacrimal glands, the Meibomian glands, the conjunctiva, and the corneal surface. Patients who are diagnosed and treated early generally maintain significantly better long-term outcomes than those who delay care until severe damage has occurred.

If you have had an allogeneic stem cell or bone marrow transplant and are experiencing any persistent eye symptoms — even mild ones — early evaluation is important.

Graft-versus-host disease causes some of the most severe ocular surface disease we treat. When eyes need a specialty lens to vault and protect the cornea, our affiliated practice Michigan Contact Lens fits scleral lenses specifically for GVHD patients. Dr. Kresch cares for patients at both practices, keeping your dry eye treatment and lens fitting under one doctor.

Frequently Asked Questions

Q: I had a transplant but do not have GVHD anywhere else. Could I still get ocular GVHD? Yes — ocular GVHD can occur in isolation or alongside GVHD in other organs. Some patients have eye involvement as their primary or earliest manifestation of chronic GVHD.

Q: How soon after transplant does ocular GVHD usually appear? Most commonly within the first 1 to 3 years after transplant, but it can occur as early as a few months or as late as many years post-transplant. Continued monitoring is important throughout the post-transplant period.

Q: Will my oncologist manage this for me? Your oncologist manages systemic GVHD and overall transplant care. Specialized eye care for ocular GVHD requires a dry eye specialist. Coordinated care between the two providers consistently produces better outcomes than either working alone.

Q: Are scleral lenses really worth it? For many patients with ocular GVHD, yes — they are often the single most impactful intervention. The continuous corneal hydration and mechanical protection that scleral lenses provide cannot be replicated by any eye drop or medication.

Q: Will my dry eye get better as my GVHD improves? Improving systemic GVHD typically helps the ocular component, but eye-specific treatment is still usually needed. Some damage (gland destruction, surface scarring) is not reversed by systemic treatment alone.

Q: Can ocular GVHD threaten my vision? Yes, in severe cases. Untreated ocular GVHD can cause corneal scarring, persistent epithelial defects, and even corneal melt — all of which can affect vision. Early treatment is the best way to prevent vision-threatening complications.

Q: Will insurance cover treatment? The diagnostic evaluation is typically covered by medical insurance because of the underlying GVHD diagnosis. Many treatments (prescription drops, punctal plugs, scleral lenses for documented medical indications) may be covered by medical insurance. We help with insurance coordination.